What to Expect, Week by Week
The most-searched GLP-1 question is some version of "what should I expect?" The uncertainty is understandable — you are starting a medication that will change your appetite, your body, and potentially your relationship with food. Knowing the clinical timeline helps you distinguish normal adjustment from problems worth reporting to your doctor.
This timeline is based on typical responses in the STEP, OASIS, and SURMOUNT clinical trials, combined with real-world clinical experience. Your individual experience may vary, and that is normal. This is a framework, not a guarantee.
Week 1-2: The Adjustment Phase
What is happening: You are starting at the lowest dose (semaglutide 0.25mg weekly, tirzepatide 2.5mg weekly, or the equivalent oral starting dose). This is a titration dose — not the therapeutic dose. Its purpose is to let your body adjust to the medication gradually.
What you may feel: Mild nausea is the most common early side effect, typically occurring in the hours after injection and lasting 1-3 days. Some patients feel slightly "off" — reduced appetite, mild GI discomfort, a subtle sense that their stomach is working differently. Others feel nothing at all.
What to expect on the scale: Do not expect significant weight loss yet. Some patients lose 2-4 pounds (mostly water and reduced food volume). Others see no change. Both are normal at this dose.
When to call your doctor: Persistent vomiting that prevents you from keeping food or water down, severe abdominal pain, or signs of an allergic reaction (rash, swelling, difficulty breathing). These are uncommon but warrant immediate attention.
Week 3-4: Appetite Changes Begin
What is happening: Even at the starting dose, many patients begin to notice a shift in appetite. Food becomes less urgent. You may find yourself eating smaller portions naturally, thinking about food less frequently, or losing interest in snacking.
What you may feel: The "food noise" — the constant background hum of thinking about your next meal — begins to quiet. This is one of the most commonly reported subjective experiences. Many patients describe it as revelatory: for the first time, they are not constantly fighting hunger.
What to expect on the scale: At the end of the first month, a total loss of 3-7 pounds is typical. Some patients see more, some less.
What to tell your doctor: How you are tolerating the medication, whether you are experiencing any GI side effects, and whether your appetite has changed. This information helps your prescriber decide the pace of dose escalation.
Nutrition Checkpoint:
Even though your appetite is suppressed, you still need adequate nutrition. Start prioritizing protein at every meal now — before you reach higher doses where appetite suppression is stronger. Aim for at least 60-80 grams of protein daily at this stage. Hydration is equally important: GI side effects can cause fluid loss, and many patients under-drink when they are not hungry.
Month 2: Dose Escalation and Visible Progress
What is happening: Most titration schedules increase the dose at the one-month mark. For injectable semaglutide, this typically means moving from 0.25mg to 0.5mg. For tirzepatide, from 2.5mg to 5mg. Each increase may temporarily re-introduce mild side effects.
What you may feel: A noticeable deepening of appetite suppression. Some patients report changes in food preferences — reduced desire for fried foods, sweets, or alcohol. Energy levels may improve as metabolic markers begin shifting. Constipation is common at this stage and responds well to fiber supplementation and adequate hydration.
What to expect on the scale: Cumulative weight loss of 5-12 pounds from baseline is typical by the end of month two. The rate of loss often accelerates compared to month one as the dose increases.
What labs to consider: If your prescriber did not run baseline labs before starting treatment, request them now: comprehensive metabolic panel, A1C, lipid panel, thyroid panel. These establish a reference point for tracking your response over time.
Month 3: Meaningful Clinical Change
What is happening: You may be approaching or reaching your first significant dose milestone (semaglutide 1.0mg, tirzepatide 7.5-10mg). This is where many patients cross the threshold from "noticeable" to "meaningful" weight loss — typically 5% or more of starting body weight.
What you may feel: Side effects from earlier dose increases should be stabilizing. Your new eating patterns are becoming routine. Clothes may fit differently. People in your life may start noticing changes. Metabolically, your blood pressure, blood sugar, and lipid levels are likely improving.
What to expect on the scale: Cumulative loss of 8-18 pounds from baseline, depending on your starting weight and individual response. Patients starting at higher body weights often see larger absolute losses.
The Three-Month Check-In Conversation:
Month three is a natural checkpoint for assessing your trajectory. If you have lost 5% or more of your starting weight, you are responding well. If you have lost less than 3%, discuss whether a faster titration, a medication switch, or investigation of confounding factors is warranted. Do not wait six months to have this conversation.
What Comes After 90 Days
The first three months establish the foundation. After this period:
- Months 4-6: Continued dose escalation toward the therapeutic target. Weight loss continues at a steady pace. This is when most patients reach the dose where long-term trials showed their best results.
- Months 7-12: Many patients approach their maximum weight loss during this window. Plateaus are common and normal. Your doctor should be monitoring body composition and metabolic markers, not just scale weight.
- Beyond 12 months: Transition from active weight loss to maintenance. Your prescriber may discuss dose adjustment, switching to an oral formulation for convenience, or the role of long-term therapy in maintaining your results.
Ready to Start Your GLP-1 Journey?
Compare licensed telehealth providers offering comprehensive GLP-1 programs with clinical support through every phase of treatment.
Compare Providers →